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Background. Disease recurrence remains the major
cause of death in adults with acute myeloid leukae-
mia (AML) treated using either intensive chemother-
apy (IC) or allogenic stem cell transplantation (allo-
SCT).
Aims. The timely delivery of maintenance drug or
cellular therapies represent emerging strategies
with the potential to reduce relapse after both
treatment modalities, but whilst the determinants
of overall relapse risk have been extensively char-
acterized the factors determining the timing of
disease recurrence have not been characterized.
Materials and Methods. We have therefore examined,
using a series of sequential landmark analyses,
relapse kinetics in a cohort of 2028 patients who
received an allo-SCT for AML in CR1 and sepa-
rately 570 patients treated with IC alone.
Results. In the first 3 months after allo-SCT, the
factors associated with an increased risk of relapse
included the presence of the FLT3-ITD (P < 0.001),
patient age (P = 0.012), time interval from CR1 to
transplant (P < 0.001) and donor type (P = 0.03).
Relapse from 3 to 6 months was associated with a
higher white cell count at diagnosis (P = 0.001),
adverse-risk cytogenetics (P < 0.001), presence of
FLT3-ITD mutation (P < 0.001) and time interval to
achieve first complete remission (P = 0.013). Later
relapse was associated with adverse cytogenetics,
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mutated NPM1, absence of chronic graft-versus-
host disease (GVHD) and the use of in vivo T-cell
depletion. In patients treated with IC alone, the
factors associated with relapse in the first
3 months were adverse-risk cytogenetics
(P < 0.001) and FLT3-ITD status (P = 0.001). The
factors predicting later relapse were the time
interval from diagnosis to CR1 (P = 0.22) and time
interval from CR1 to IC (P = 0.012).
Discussion and Conclusion. Taken together, these data
provide novel insights into the biology of disease
recurrence after both allo-SCT and IC and have the
potential to inform the design of novel maintenance
strategies in both clinical settings.
Keywords: Acute myeloid leukaemia, stem cell trans-
plantation, intensive chemotherapy, kinetics,
maintenance therapy.
Introduction
Disease relapse remains the major cause of treat-
ment failure in adults with acute myeloid leukaemia
(AML) receiving allogeneic stem cell transplantation
(allo-SCT) or intensive chemotherapy (IC) delivered
with curative intent [1, 2]. Although the factors
determining overall relapse risk after both allo-
SCT and IC have been well defined [3], it is
unknown whether they contribute equally to the
risk of early and late relapse or whether these
represent distinct biological entities. Such infor-
mation would inform both our understanding of
the biology of disease relapse and the development
of novel strategies designed to reduce the risk of
relapse.
Allo-SCT remains the most effective curative option
in adults with high-risk AML but up to 70% of
patients still relapse [3]. Strategies which reduce the
risk of disease recurrence are consequently urgently
required [4]. Disease biology is an important deter-
minant of overall relapse risk in patients treated
with IC, consequent presumably upon genetically
mediated chemoresistance [5], but whether distinct
molecular or cellular factors determine relapse
kinetics is not known. In patients allografted for
AML, the potential mechanisms contributing to
disease relapse and its kinetics are more complex.
A number of distinct biological mechanisms have
the potential to mediate disease recurrence after
allo-SCT which can be broadly categorized as resis-
tance of host malignant hematopoiesis to compo-
nents of the conditioning regimen or the abrogation
of a graft-versus-leukaemia (GVL) effect [6]. Dis-
ease- and transplant-specific factors, such as pre-
sentation karyotype and conditioning regimen
intensity, respectively, have previously been shown
to predict overall relapse risk after allo-SCT, but
their impact on relapse kinetics has not been
studied and the detailed mechanism by which they
contribute to disease recurrence remains poorly
understood [7,8]. Consequently, detailed
characterization of the contribution of disease-
and transplant-specific factors to the kinetics of
disease relapse may provide additional insights into
the biology of both early and late disease relapse
after both allo-SCT and IC.
Scheduled administration of cellular interventions,
such as donor lymphocyte infusions (DLI), or
pharmacological therapies in the early post-trans-
plant period represents one of the most promising
novel approaches with the potential to reduce the
risk of disease relapse after allo-SCT [9]. Similarly,
administration of both pharmacological and
immunotherapeutic maintenance therapies in
patients treated with IC alone represents promising
new treatment strategies and will plausibly be
informed by a more detailed understanding of the
factors determining the kinetics of relapse in this
setting. We now report the first systematic study of
factors determining the kinetics of disease relapse
in patients with AML whose definitive therapy
consisted either of allo-SCT or IC.
Patients and methods
Registries
This was a retrospective multicentre analysis. Data
were provided and approved for this study by both
the Acute Leukaemia Working Party (ALWP) of the
EBMT and the HOVON-SAKK cooperative study
group. The EBMT is a voluntary working group of
more than 500 transplant centres that are required
to report outcomes on all consecutive stem cell
transplantations they perform and the HOVON_-
SAKK a Dutch-Belgian-Swiss cooperative study
group performing trials for adult patients with
haematological malignancies. The study protocols
were approved by the institutional review board at
each site and complied with country-specific
requirements. Long-term follow-up data from both
the ALWP and HOVON-SAKK are reported on an
annual basis, and audits are years routinely per-
formed to determine the accuracy of the reported
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data. The study was conducted in accordance with
the declaration of Helsinki and Good Clinical
Practice guidelines. All patients provided written
informed consent authorizing the use of their
personal information for research purposes.
Patients
Using the EBMT Registry we identified 20 341
adult patients (age ≥ 18) with de novo non-APML
AML in first complete remission (CR1) who under-
went transplantation between 2000 and 2015,
using bone marrow or GCSF mobilized peripheral
blood stem cells from HLA-matched sibling or
unrelated donors using either a myeloablative
conditioning (MAC) or reduced intensity (RIC) reg-
imen based on published criteria [10]. Cytogenetic
data were available from a diagnostic bone marrow
aspirate in 9218 patients permitting risk stratifi-
cation according to MRC criteria [11]. Of these,
information concerning the number of courses of
induction chemotherapy was available in 6191
patients. Of this cohort, mutational analysis of
the NPM1 gene and information concerning the
presence or absence of a FLT3-ITD was available in
2028 patients who are reported in this analysis
(Table 1). The median age of the allo-SCT cohort
was 51 (18–77) years. The white cell count (WBC) at
diagnosis was 12.4 9 109/L. Eighty-five per cent of
patients had good-/intermediate-risk cytogenetics
at diagnosis. The interval from diagnosis to trans-
plant was 151 (43–731) days. The interval from
time of acquisition of CR to transplant was 98 (11–
357) days. Of note, the time from diagnosis to
acquisition of CR1 was correlated with the number
of courses of induction chemotherapy delivered.
Eight hundred and eighty-six patients were trans-
planted using a sibling donor and 1142 from an
adult-matched unrelated donor (Table 1). One
thousand and forty-one patients were transplanted
using a myeloablative conditioning (MAC) and 987
a reduced intensity conditioning (RIC) regimen.
Four hundred and thirty-eight patients received
TBI as component of their conditioning regimen:
216 in the context of a MAC regimen and 222 as
part of a RIC regimen. The commonest MAC
regimens utilized were a myeloablative combina-
tion of busulphan (Bu) and cyclophosphamide (Cy)
(n = 439), Bu and fludarabine (Flu) (n = 270) or Cy
and TBI (n = 210). The most frequently utilized RIC
regimens were a combination of Flu and BU
(n = 535), Flu and TBI (n = 203), Flu and Melpha-
lan (n = 101). One thousand one hundred and
seventy-six patients received in vivo GVHD
prophylaxis utilizing anti-thymocyte globulin
(ATG) (n = 1093) or alemtuzumab (n = 83). No
patients received in vitro T-cell depletion. Disease
relapse was diagnosed using conventional mor-
phological criteria. Pretransplant measurable dis-
ease (MRD) data were not available.
In a separate analysis, factors determining the
kinetics of relapse were studied in a comparable
cohort of adults treated on the HOVON-SAKK
prospective clinical trials AML29, AML42, AML43,
AML81 and AML92 which accrued patients during
the time period 2000-2010. Postremission treat-
ment was applied according to a risk-adapted
strategy in the HOVON-SAKK studies: (i) patients
with AML classified as favourable risk, according to
cytogenetic and molecular analysis, were planned
for a third cycle of chemotherapy; (ii) intermediate-
risk patients were preferentially treated by
allo-SCT using a human leucocyte antigen (HLA)-
matched sibling donor or a fully HLA-matched
unrelated donor if available; (iii) patients with
adverse-risk AML proceeded to allo-SCT using
either a sibling donor, unrelated donor, or cord
blood grafts; (iv) patients alternatively received an
auto-SCT or a third cycle of chemotherapy if no
suitable donor was available.
A total of 570 adults who achieved remission (CR1)
after induction chemotherapy whose subsequent
treatment consisted of IC consolidation in the form
of mitoxantrone 10 mg m2 for 5 days and etopo-
side 100 mg m2 for 5 days were included in this
study (Table 2). The median age of patients in this
cohort was 47 (16–77) years. The WBC at diagnosis
was 12 9 109/L. Seventy-eight per cent of patients
had good-/intermediate-risk cytogenetics at diag-
nosis. The median time from diagnosis to acquisi-
tion of CR1 was 35 days (19–140 days), and the
median time from acquisition of CR to the com-
mencement of IC was 59 days (0–370). Patients
treated on HOVON studies after 2010 were not
included because of a change in the intensive
chemotherapy schedule after this date.
Statistical methods
A series of landmark analyses were performed at 3,
6 and 12 months post-transplant in order to iden-
tify prognostic factors of relapse for patients alive
and well at the beginning of each time interval. The
probabilities of relapse were calculated using the
cumulative incidence estimator to accommodate
for death as a competing risk. Factors predicting
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relapse were studied using Cox regression model
including time-dependent variables. The variables
included in the regression analysis of the trans-
plant cohort were age, WBC at diagnosis, time from
diagnosis to CR, time from CR to transplant, female
donor to male recipient, donor type, CMV status of
patient and donor, conditioning regimen, NPM1
and FLT3-ITD mutation status, adverse-risk cyto-
genetics, in vivo T-cell depletion, stem cell source,
previous acute GVHD grade II-IV and previous
chronic GVHD. The variables included in regres-
sion analysis of the IC cohort were age, sex, WBC at
diagnosis, adverse-risk cytogenetics, FLT3-ITD,
NPM1, number of induction cycles to CR, year of
chemotherapy, time from diagnosis to CR and time
from CR to chemotherapy. A backward stepwise
procedure was used for variable selection with a P-
value of <0.05. The purpose of this study was to
identify prognostic factors influencing relapse risk
for patients alive at different time-points after allo-
SCT or IC. Time post-transplant in smaller inter-
vals or as a continuous parameter could not be
studied since the number of events would be too
low for analysis. In the transplant population,
chronic GVHD was studied as a fixed variable in
landmark analyses and only taken into account if it
was documented prior to the specific landmark
under examination.
Results
Relapse incidence according to time in patients with newly diagnosed
AML treated with allo-SCT
With a median follow-up of 36 months, 519 (26%)
of the 2028 informative patients relapsed after allo-
SCT resulting in a 3-year cumulative incidence of
relapse (CIR) of 26% [95% CI: 24–28]. The corre-
sponding estimated 3-year cumulative incidence of
Table 1 (a) Characteristics of 1057 patients undergoing
allo-SCT. (b) Transplant characteristics of allo-SCT
patients
Allo-SCT (N = 2028)
(a)
Sex
Male 1042 51%
Female 984 49%
Age (years)
Median 51
Range 18–77
WBC at diagnosis
Median 12.4
Range 0.1–780
Year of chemotherapy
Median 2012
Range 2000–2015
Cytogenetics
Good 41 2%
Intermediate 1679 83%
Adverse 308 15%
NPM1-FLT3-ITD
Pos/Neg 153 8%
Pos/Pos 536 26%
Neg/Pos 278 14%
Neg/Neg 1061 52%
Time from CR to PRT (days)
Median 98
Range 11–357
(b)
Donor
HLA-identical Sib 886 44%
MUD 1142 56%
Female donor to
male recipient
327 16%
Conditioning
MAC 1041 51%
RIC 987 49%
TBI
Yes 438 22%
No 1590 78%
Stem cell source
BM 418 21%
PB 1610 79%
Table 1 (Continued )
Allo-SCT (N = 2028)
CMV donor/recipient
Pos/Neg 218 11%
Pos/Pos 738 37%
Neg/Pos 507 25%
Neg/Neg 547 27%
In vivo T-cell depletion
No 847 42%
Yes 1176 58%
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nonrelapse mortality was 15% resulting in a 59%
3-year probability of leukaemia free survival. The
CIR in the first 3 months post-transplant was 7.0%
(95% CI: 5.8–8.0%), 7.8% (95% CI: 6.6–9.1%)
between 3 and 6 months, 7.4% (95% CI: 6.2–
8.8%) between 6 and 12 months and 9.7% (95%
CI: 8–11.6) beyond 12 months, respectively. Over-
all 73.7% of patients destined to relapse did so
within the first year post-transplant.
Factors predicting relapse risk according to time after allogeneic SCT
The overall factors predicting disease relapse for
the whole population were the presence of a
FLT3-ITD mutation at diagnosis (P < 0.001), the
absence of an NPM1 mutation (P < 0.001),
adverse-risk cytogenetics at diagnosis (P < 0.001),
time from acquisition of CR1 to transplant
(P < 0.001), a higher WBC at diagnosis (P =
0.005), age at transplant (P = 0.02) and chronic
GVHD studied as a time-dependent variable
(P = 0.001). Of note conditioning regimen inten-
sity as not correlated with relapse risk in the
studied population.
Using landmark analyses, the factors determining
the relapse risk within the first 3 months post-
transplant were patient age (P = 0.012), interval
from CR1 to transplant (P < 0.001), the presence
of a FLT3-ITD mutation at diagnosis (P < 0.001)
and donor type (P = 0.033) with a lower risk of
relapse noted in recipients of a MUD (Table 3). In
allo-SCT recipients who relapsed between 3 and
6 months post-transplant, factors associated with
relapse were higher WBC at diagnosis (P = 0.001),
adverse-risk cytogenetics (P < 0.001), the presence
of a FLT3-ITD mutation at diagnosis (P < 0.001)
and the time interval from diagnosis to acquisition
of CR1 (P = 0.013). The risk of relapse 6–
12 months after transplant was associated with
adverse cytogenetics (P = 0.003), the absence of
an NPM1 mutation (P = 0.013) and the absence of
chronic graft-versus-host disease (GVHD)
(P < 0.001). Finally, a longer time from CR1
acquisition to transplant (P = 0.016), the absence
of an NPM1 mutation (P = 0.018), adverse cytoge-
netics (P = 0.002), the use of in vivo TCD
(P = 0.037) and the absence of GVHD (P = 0.037)
predicted for relapse risk for relapse more than
12 months post-transplant. Of interest when the
analysis is restricted to the 987 patients trans-
planted using a RIC regimen many of the factors
determining disease relapse remain the same but
distinct factors emerge in this population. Thus,
the factors determining relapse within the first
3 months after a RIC allograft were time from CR1
to transplant (P = 0.02), the utilization of in vivo T-
cell depletion (P = 0.013), higher WBC at diagnosis
(P = 0.005), the presence of a FLT3-ITD mutation
at diagnosis (P = 0.008) and the absence of an
NPM1 mutation (P = 0.02). For patients relapsing
6–12 months post-transplant, the factors were the
absence of chronic GVHD before 6 months post-
transplant (P < 0.001) and the absence of an
NPM1 mutation (P = 0.03). Finally, the use of
in vivo T-cell depletion was associated with a
trend for a higher relapse rate after 12 months
(P = 0.09).
Table 2 Characteristics of 570 patients treated with
intensive chemotherapy alone
Chemotherapy (N = 570)
Sex
Male 296 52%
Female 274 48%
Age (years)
Median 47
IQ Range 16–77
WBC at diagnosis
Median 12
IQ Range 0.3–510
Year of chemotherapy
Median 2004
IQ Range 2000–2010
Cytogenetics
Good 112 18%
Intermediate 340 60%
Adverse 91 16%
Missing 27 5%
NPM1-FLT3-ITD
Pos/Neg 54 9%
Pos/Pos 48 8%
Neg/Pos 25 4%
Neg/Neg 184 32%
Missing 259 45%
Time from diagnosis to CR (days)
Median 35
IQ range 19–140
Time from CR to PRT (days)
Median 59
IQ range 0–370
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Relapse incidence according to time in patients with newly diagnosed
AML treated with IC
In patients treated with IC alone, a total of 302
(53%) patients relapsed with a median follow-of
86 months. The CIR at 3 years was 54% [95% CI:
50–58). Two hundred and twelve (80%) patients
relapsed within the first year after completion of IC.
Factors significantly associated with relapse in the
first 3 months after chemotherapy were adverse-
risk cytogenetics (P < 0.001) and the presence of a
FLT3-ITD mutation at diagnosis (P = 0.001) which
were also the factors that predicted for relapse
within 3 and 6 months (both P < 0.001). The time
interval from diagnosis to CR1 and from CR1 to
consolidation (P = 0.012) was inversely associated
Table 3 Factors determining kinetics of disease relapse after allo-SCT and IC
P-value HR 95% CI
Allo-SCT
1. Factors influencing relapse within 3 months
FLT3-ITD <0.001 2.19 1.56–3.07
Age (per decade) 0.012 1.19 1.04–1.37
Time interval CR1 to transplant (months) <0.001 0.79 0.70–0.88
Unrelated donor 0.033 0.69 0.49–0.97
2. Factors influencing relapse within 3–6 months
WBC at diagnosis (per 10) 0.001 1.02 1.01–1.04
Adverse-risk cytogenetics <0.001 2.47 1.73–3.51
FLT3-ITD <0.001 1.85 1.35–2.53
Time interval diagnosis to CR1 (months) 0.013 1.15 1.03–1.29
3. Factors influencing relapse within 6–12 months
cGVHD before 6 months <0.001 0.29 0.19–0.46
Mutated NPM1 0.013 0.53 0.33–0.87
Adverse-risk cytogenetics 0.003 1.97 1.26–3.07
4. Factors influencing relapse after 12 months
Time interval CR1 to transplant (months) 0.016 0.88 0.79–0.98
Adverse-risk cytogenetics 0.002 1.94 1.27–2.97
cGVHD before 12 months 0.019 0.66 0.46–0.93
Mutated NPM1 0.018 0.62 0.41–0.92
In vivo TCD 0.037 1.48 1.03–2.15
Chemotherapy
1. Factors influencing relapse within 3 months
Adverse-risk cytogenetics <0.001 3.90 2.16–10.75
FLT3-ITD 0.001 4.82 1.76–8.68
Age (per decade) 0.059 1.43 0.99–2.07
WBC at diagnosis (per 10) 0.063 1.03 1.00–1.07
2. Factors influencing relapse within 3–6 months
FLT3-ITD <0.001 3.69 1.90–7.19
Adverse-risk cytogenetics <0.001 3.29 1.78–6.08
Mutated NPM1 0.084 0.52 0.24–1.09
3. Factors influencing relapse within 6–12 months
Time interval diagnosis to CR1 (months) 0.022 0.38 0.17–0.87
Time interval CR1 to chemo (months) 0.012 0.54 0.33–0.87
Italicised text refers to gene mutations studied.
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with relapse between six and twelve months post-
treatment.
Discussion
This analysis demonstrates that distinct leukae-
mia- and transplant-specific factors contribute to
the risk of early and late relapse post-transplant.
Notably, the clinical and genetic attributes of the
leukaemia which are associated with an increased
risk of early relapse post-transplant differ from
those correlated with later relapse and are similar
to those which predict the kinetics of relapse in
patients treated with chemotherapy alone. It also
appears that factors previously associated with an
increased risk of relapse post-transplant, such as
the absence of chronic GVHD, exert this effect at
specific time-points post-transplant. These obser-
vations are consistent with disease relapse occur-
ring as a dynamic interplay of tumour- and
transplant-associated factors throughout the
post-transplant period and identify specific, poten-
tially manipulable contributors to relapse at dis-
tinct time-points postallograft.
The biology of disease relapse after allo-SCT
remains poorly understood. Our data suggest that
the specific characteristics of the leukaemia predis-
pose to early relapse post-transplant, although the
underlying biological mechanisms remain specula-
tive. The increased risk of early relapse associated
with the presence of an adverse-risk karyotype or
FLT3-ITDmaybe consequent oneither ahigher level
of pretransplant MRD [12] or rapid expansion of the
tumour cells not eradicated by the conditioning
regimen. Another possibility is that the potency of
the allo-immune response is modulated by specific
disease characteristics and that this contributes to
both absolute relapse risk and its timing. In this
context, it is of interest that mutations in IDH1 and
other leukaemia-associated genes modulate DNA
methylation in leukaemic blasts and potentially
their ability to be recognized by the donor allo-
immune response [13] consistent with this hypoth-
esis. On the other hand, a previousHOVONanalysis
identified a similar reduction in relapse risk after
allo-SCT in different AML risk categories indicating
that the GVL effect is similarly exerted in adverse,
intermediate and favourable risk AML [7] and
determined by differences in minor and major
HLA-antigens rather than an interplay between
alloreactivity and disease biology. Nevertheless,
absolute percentages of relapse are higher in poor-
risk AMLwith themajority of relapses after allo-SCT
occurring within the first year after transplantation.
The similar determinants of relapse early after
chemotherapy and after transplant, highlight the
possibility that tumour growth kinetics, determined
by specific mutations including the FLT3-ITD, may
play a centrally important role in the early blunting
of a GVL effect by outcompeting the expansion of
alloreactive T cells in the immediate post-transplant
period. Our data also demonstrate that the timing of
relapse is driven by distinct transplant-specific
factors. Of interest, the use of an adult unrelated
donor is associated with a decreased risk of disease
relapse in the first few months post-transplant
consistent with a recent large analysis from the
EBMT [14] Similarly, it is striking that the develop-
ment of chronic GVHD reduces relapse risk within
the first year post-transplant. When the analysis
was extended to smaller population of patients
allografted using aRIC regimen, although statistical
power was lost broadly similar disease- and trans-
plant-specific factors determining relapse kinetics
were identified, althoughof interest theutilization of
in vivo TCD emerged as a significant risk factor in
this distinct setting. Of interest, the use of a RIC
regimen was not associated with an increased risk
of disease relapse which is consistent with two
recent prospective randomized trials but at variance
with the findings of a recently reported US CTN
study [15–17]. Taken together, these data suggest
the existence of a complex interaction between
leukaemia- and transplant-specific factors in the
maintenance of disease remission post-transplant
and identify potential manipulable pathways at dif-
ferent stages post-transplant. The retrospective nat-
ure of this analysis limits its interpretation, and
prospective studies will important to validate the
observationswehavemadeand limit selectionbias. It
is important also to note that the age of the cohort
treated with IC in this study is lower than the
transplant cohort, although this may be of less
relevance given the increasingage atwhichallogeneic
transplants can now be delivered with relative safety
[18]. Future studies on larger patient cohorts with
more detailedmolecular analyses will provide impor-
tant information concerning whether specific molec-
ular abnormalities predict either relapse risk or its
kinetics. Specifically, the prospective incorporation
ofpretransplantMRDassessmentwill provide impor-
tant information concerning the relative importance
of the contrasting mechanisms of early and late
relapse we have identified.
There is increasing recognition that post-trans-
plant pharmacological or cellular intervention may
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represent an important novel strategy by which the
risk of disease relapse is reduced in patients
undergoing allo-SCT as well as those treated with
chemotherapy alone. Such approaches include both
the administration of prophylactic DLI as well as the
use of biologically targeted therapies such as FLT3
inhibitors or epigenetic therapies such as azaci-
tidine and panobinostat [19–23]. Similarly, in
patients treated with intensive chemotherapy alone,
there have been encouraging data reported utilizing
maintenance strategies employing both azacitidine
and decitabine [24, 25]. A major challenge in the
safe and effective delivery of novel drug and cellular
therapies particularly after an allogeneic transplant
is the toxicity associated with both modalities. Of
particular, concern is the substantial risk of severe
GVHD which is observed when DLI is administered
early post-transplant, but it is also the case that the
tolerability of pharmacological interventions in the
form of maintenance therapy can be problematic in
patients treated with intensive chemotherapy alone.
Thus, the ability of our data to identify patients at
particular risk of early and later relapse can be
predicted to be of value in the design of novel
treatment strategies particularly with regard to the
timing of post-transplant interventions. Specifically,
our data emphasize the importance of early inter-
vention in patients allografted for AML associated
with a FLT3-ITD or adverse-risk cytogenetics given
the striking increase in relapse in the first 3 months
post-transplant in this subgroup of patients. Con-
sequently, the encouraging preliminary data
reported using sorafenib in patients transplanted
for FLT3-ITD-positive AML are encouraging – in
particular the reported ability to administer this
agent relatively early post-transplant [21]. In the
light of the substantial risk of GVHD associated
with the early administration of DLI and the prac-
ticalities of immunosuppression withdrawal such a
group of patients are more likely to benefit from
pharmacological intervention with agents such as
sorafenib or DNMT inhibitors [26]. Alternatively, it
may be possible to identify a population of patients
likely to relapse later, for whom DLI is an important
alternative intervention.
Our data provide novel insights into the mechanism
of disease relapse and identify a complex interaction
of factors determining the timing of disease relapse
postallograft. Specifically, they demonstrate that
distinct and potentially manipulable tumour and
transplant-related factors play contrasting roles in
the determining the timing of relapse post-trans-
plant. These observations can inform the design of
novel strategies aimed at reducing the risk of
relapse postallograft and importantly imply that a
nuanced approach should be taken with specific
reference to the timing of intervention according to
disease and transplant factors.
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